ES2132308T3 - 4-(2-cloro-3-ciano-fenil)-1,4-dihidro-2,6-dimetil-piridina-3,5-dicarboxilato de isopropilo y 2-metoxietilo. - Google Patents

4-(2-cloro-3-ciano-fenil)-1,4-dihidro-2,6-dimetil-piridina-3,5-dicarboxilato de isopropilo y 2-metoxietilo.

Info

Publication number
ES2132308T3
ES2132308T3 ES94118671T ES94118671T ES2132308T3 ES 2132308 T3 ES2132308 T3 ES 2132308T3 ES 94118671 T ES94118671 T ES 94118671T ES 94118671 T ES94118671 T ES 94118671T ES 2132308 T3 ES2132308 T3 ES 2132308T3
Authority
ES
Spain
Prior art keywords
dihydro
chlorine
cyan
phenyl
metoxietilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94118671T
Other languages
English (en)
Inventor
Heinrich Dr Meier
Wolfgang Dr Hartwig
Bodo Dr Junge
Rudolf Dr Schohe-Loop
Zhan Dr Gao
Bernard Dr Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4342194A external-priority patent/DE4342194A1/de
Priority claimed from DE19944424677 external-priority patent/DE4424677A1/de
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2132308T3 publication Critical patent/ES2132308T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL NUEVO COMPUESTO RAC ISOPROPIL - (2 - METOXIETIL) - 4 - (2 - CLORO - 3 - CIANO FENIL) - 1,4 - DIHIDRO - 2,6 - DIMETILPIRIDINA - 3,5 DICARBOXILATO Y SUS ENANTIOMEROS PUROS, PROCEDIMIENTO PARA SU ELABORACION Y SU UTILIZACION COMO MEDICAMENTO, EN PARTICULAR PARA EL TRATAMIENTO DE ENFERMEDADES CEREBRALES Y NEURONALES ASI COMO NUEVOS PRODUCTOS INTERMEDIOS PARA SU ELABORACION.
ES94118671T 1993-12-10 1994-11-28 4-(2-cloro-3-ciano-fenil)-1,4-dihidro-2,6-dimetil-piridina-3,5-dicarboxilato de isopropilo y 2-metoxietilo. Expired - Lifetime ES2132308T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4342194A DE4342194A1 (de) 1993-12-10 1993-12-10 Halogen-phenyl-substituierte 1,4-Dihydropyridine
DE19944424677 DE4424677A1 (de) 1994-07-13 1994-07-13 Isopropyl-(2-methoxyethyl)-4-(2-chlor-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridin-3,5-dicarboxylat

Publications (1)

Publication Number Publication Date
ES2132308T3 true ES2132308T3 (es) 1999-08-16

Family

ID=25931956

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94118671T Expired - Lifetime ES2132308T3 (es) 1993-12-10 1994-11-28 4-(2-cloro-3-ciano-fenil)-1,4-dihidro-2,6-dimetil-piridina-3,5-dicarboxilato de isopropilo y 2-metoxietilo.

Country Status (35)

Country Link
US (1) US5665740A (es)
EP (1) EP0657430B1 (es)
JP (1) JP3751041B2 (es)
KR (1) KR100332325B1 (es)
CN (2) CN1056606C (es)
AT (1) ATE180774T1 (es)
AU (1) AU686976B2 (es)
BG (1) BG62487B1 (es)
CA (1) CA2137525C (es)
CO (1) CO4290426A1 (es)
CU (1) CU22713A3 (es)
CZ (1) CZ286065B6 (es)
DE (1) DE59408350D1 (es)
DK (1) DK0657430T3 (es)
DZ (1) DZ1831A1 (es)
EE (1) EE03192B1 (es)
ES (1) ES2132308T3 (es)
FI (1) FI105681B (es)
GR (1) GR3030436T3 (es)
HR (1) HRP940967B1 (es)
HU (1) HU215593B (es)
IL (1) IL111922A (es)
LV (1) LV11321B (es)
MA (1) MA23392A1 (es)
MY (1) MY111976A (es)
NO (1) NO302362B1 (es)
NZ (1) NZ270087A (es)
PL (1) PL179973B1 (es)
RO (1) RO115800B1 (es)
SA (1) SA95160078B1 (es)
SK (1) SK282399B6 (es)
SV (1) SV1994000072A (es)
TN (1) TNSN94127A1 (es)
TW (1) TW412529B (es)
YU (1) YU48920B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051389A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceuticals Corporation Using of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders
WO2008058234A2 (en) * 2006-11-08 2008-05-15 Memory Pharmaceuticals Corporation Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility
WO2019104041A1 (en) * 2017-11-21 2019-05-31 Michael Ohlmeyer Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
US3932646A (en) * 1971-04-10 1976-01-13 Farbenfabriken Bayer Ag Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2508181A1 (de) * 1975-02-26 1976-09-09 Bayer Ag 1,4-dihydropyridincarbonsaeurearal- kylester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
DE2935451A1 (de) * 1979-09-01 1981-03-19 Bayer Ag, 5090 Leverkusen Optisch aktive 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arneimittel
DE3208628A1 (de) * 1982-03-10 1983-09-22 Bayer Ag, 5090 Leverkusen Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3239273A1 (de) * 1982-10-23 1984-04-26 Bayer Ag, 5090 Leverkusen Tetrahydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5137889A (en) * 1983-12-02 1992-08-11 Otsuka Pharmaceutical Co., Ltd. Dihydropyridine derivatives and process for preparing the same
DE3718398A1 (de) * 1987-06-02 1988-12-22 Troponwerke Gmbh & Co Kg Neue kombinationspraeparate mit antidepressiver wirkung
US5114946A (en) * 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
DE3806277A1 (de) * 1988-02-27 1989-09-07 Troponwerke Gmbh & Co Kg Verwendung von 1,4-dihydropyridin-derivaten
DE4011695A1 (de) * 1990-04-11 1991-10-17 Bayer Ag Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung
FR2671349B1 (fr) * 1991-01-09 1993-04-23 Lafon Labor Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
DE4125271A1 (de) * 1991-07-31 1993-02-11 Bayer Ag Neue n-alkylierte 1,4-dihydropyridindicarbonsaeureester

Also Published As

Publication number Publication date
IL111922A (en) 1999-05-09
AU8030694A (en) 1995-06-15
HRP940967A2 (en) 1997-08-31
JP3751041B2 (ja) 2006-03-01
BG99249A (en) 1995-09-29
YU71794A (sh) 1996-10-18
MY111976A (en) 2001-03-31
NO944787L (no) 1995-06-12
EE03192B1 (et) 1999-06-15
KR100332325B1 (ko) 2002-09-04
BG62487B1 (bg) 1999-12-30
FI945777A0 (fi) 1994-12-08
CN1056606C (zh) 2000-09-20
YU48920B (sh) 2002-11-15
LV11321A (lv) 1996-06-20
NO302362B1 (no) 1998-02-23
CA2137525C (en) 2005-07-12
SA95160078B1 (ar) 2006-09-25
HRP940967B1 (en) 1999-12-31
GR3030436T3 (en) 1999-09-30
CU22713A3 (es) 1996-07-05
EP0657430A1 (de) 1995-06-14
CO4290426A1 (es) 1996-04-17
LV11321B (en) 1996-12-20
IL111922A0 (en) 1995-03-15
CN1124258C (zh) 2003-10-15
DZ1831A1 (fr) 2002-02-17
NZ270087A (en) 1996-08-27
HUT70937A (en) 1995-11-28
FI945777A7 (fi) 1995-06-11
NO944787D0 (no) 1994-12-09
PL179973B1 (pl) 2000-11-30
CZ309394A3 (en) 1995-11-15
US5665740A (en) 1997-09-09
DE59408350D1 (de) 1999-07-08
DK0657430T3 (da) 1999-11-15
FI105681B (fi) 2000-09-29
SK151694A3 (en) 1995-07-11
TW412529B (en) 2000-11-21
TNSN94127A1 (en) 1995-09-21
HU215593B (hu) 1999-01-28
ATE180774T1 (de) 1999-06-15
CA2137525A1 (en) 1995-06-11
CZ286065B6 (cs) 2000-01-12
SK282399B6 (sk) 2002-01-07
AU686976B2 (en) 1998-02-12
JPH07242632A (ja) 1995-09-19
MA23392A1 (fr) 1995-07-01
RO115800B1 (ro) 2000-06-30
CN1109874A (zh) 1995-10-11
KR950017958A (ko) 1995-07-22
PL306157A1 (en) 1995-06-12
SV1994000072A (es) 1995-08-09
HU9403551D0 (en) 1995-02-28
CN1244525A (zh) 2000-02-16
EP0657430B1 (de) 1999-06-02

Similar Documents

Publication Publication Date Title
NO20053644L (no) (2S)-2-[(4S)-4-(2,2-difluorvinyl)-2-oksopyrrolidinyl ]butanamid og farmasoytisk preparat
WO2003032994A3 (de) 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
MA27676A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
DE3767839D1 (de) Pyrrolidinamid-derivate mit antipropylendopeptidase-wirkung, zusammenstellungen, die sie enthalten, verfahren zu ihrer herstellung und heilmittel, die sie enthalten.
ATE223399T1 (de) Quinazolin-4-on ampa antagonisten
ATE526981T1 (de) Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
WO2002100836A3 (en) Compounds, compositions and methods for modulating beta-amyloid production
ES2132308T3 (es) 4-(2-cloro-3-ciano-fenil)-1,4-dihidro-2,6-dimetil-piridina-3,5-dicarboxilato de isopropilo y 2-metoxietilo.
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
ATE528279T1 (de) 3-butenyl-1-aminederivate und ihre verwendung als ih modulatoren von therapie für psychiatrische erkrankungen
NO973342L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av cerebrale degenerative sykdommer
ZA891769B (en) Heterocyclic compounds
GEP20063815B (en) Novel benzothiazine and benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same
BR0317714A (pt) Oxazóis como realçadores de mglur1
EP1330454A4 (en) BENZOPYRANYLHETEROCYCLYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
IL115004A0 (en) Use of substituted 6-amino-4h-pyrans as medicaments, certain novel such compounds and their preparation
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
EP0276805A3 (en) Substituted 3-phenyl-7h-thiazoloû3,2-b¨û1,2,4¨triazin-7-ones, processes for their preparation, medicaments containing them and their use as well as some of the intermediates obtained during the preparation of said compounds
PT950053E (pt) Novos derivados de benzoilalquil-1,2,3,6-tetra-hidropiridinas
FR2710912B1 (fr) Nouveaux intermédiaires de préparation de la vitamine A et des caroténoïdes et leur procédé de préparation.
YU36499A (sh) Primena 1-/4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropirid -1-il/2-(6,7-dimetoksinaft-2-il)etana za dobijanje medikamenata za neurotrofno dejstvo

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 657430

Country of ref document: ES